Onconetix, Inc. Increase (Decrease) in Accounts Payable
Onconetix, Inc. (ONCO) reported Increase (Decrease) in Accounts Payable of $87.34 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- Onconetix, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $312.12K.
- Onconetix, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$224.78K.
- Onconetix, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$45.69K.
- Onconetix, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$775.17K, a 181.89% decline year-over-year.
- Onconetix, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$1.09M.
- Onconetix, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$1.48M, a 143.80% decline from fiscal 2023.
- Onconetix, Inc. increase (decrease) in accounts payable for fiscal 2023 was $3.37M, a 208.31% increase from fiscal 2022.
- Onconetix, Inc. increase (decrease) in accounts payable for fiscal 2022 was $1.09M, a 224.88% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $312.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $87.34K 10-Q · filed 2026-08-13 | $41.65K derived: sum of 3 quarters · filed 2026-08-13 | -$733.52K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$224.78K 10-Q · filed 2026-05-13 | -$270.47K derived: sum of 2 quarters · filed 2026-05-13 | -$1.05M derived: sum of 3 quarters · filed 2026-05-13 | -$1.06M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$45.69K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$820.85K derived: sum of 2 quarters · filed 2026-03-13 | -$832.29K derived: sum of 3 quarters · filed 2026-08-13 | -$1.09M 10-K · filed 2026-03-13 | |
| 2025-09-30 | -$775.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$786.61K derived: sum of 2 quarters · filed 2026-08-13 | -$1.05M 10-Q · filed 2025-11-13 | -$1.28M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$11.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$272.80K 10-Q · filed 2026-08-13 | -$507.81K derived: sum of 3 quarters · filed 2026-08-13 | $438.75K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$261.36K 10-Q · filed 2026-05-13 | -$496.37K derived: sum of 2 quarters · filed 2026-05-13 | $450.19K derived: sum of 3 quarters · filed 2026-05-13 | -$721.01K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$235.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $711.55K derived: sum of 2 quarters · filed 2026-03-13 | -$459.65K derived: sum of 3 quarters · filed 2026-03-13 | -$1.48M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $946.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$224.64K derived: sum of 2 quarters · filed 2025-11-13 | -$1.24M 10-Q · filed 2025-11-13 | $712.53K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$2.19M 10-Q · filed 2025-08-14 | -$234.03K derived: sum of 3 quarters · filed 2025-08-14 | $756.61K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$1.02M 10-Q · filed 2025-06-12 | $937.17K derived: sum of 2 quarters · filed 2025-06-12 | $1.93M derived: sum of 3 quarters · filed 2025-06-12 | $3.59M derived: sum of 4 quarters · filed 2025-06-12 | |
| 2023-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | $2.95M derived: sum of 2 quarters · filed 2025-06-02 | $4.61M derived: sum of 3 quarters · filed 2025-06-02 | $3.37M 10-K · filed 2025-06-02 | |
| 2023-09-30 | $990.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-10 | $2.66M derived: sum of 2 quarters · filed 2024-12-10 | $1.42M 10-Q · filed 2024-12-10 | $2.15M derived: sum of 4 quarters · filed 2024-12-10 | |
| 2023-06-30 | $1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-29 | $427.41K 10-Q · filed 2024-08-29 | $1.16M derived: sum of 3 quarters · filed 2024-08-29 | $1.03M derived: sum of 4 quarters · filed 2024-08-29 | |
| 2023-03-31 | -$1.24M 10-Q · filed 2024-05-20 | -$214.31K 10-Q · filed 2023-05-12 | -$504.68K derived: sum of 2 quarters · filed 2024-05-20 | -$635.34K derived: sum of 3 quarters · filed 2024-05-20 | -$495.40K derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $732.81K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | $602.15K derived: sum of 2 quarters · filed 2024-04-11 | $742.10K derived: sum of 3 quarters · filed 2024-04-11 | $1.09M 10-K · filed 2024-04-11 | |
| 2022-09-30 | -$130.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | $9.29K derived: sum of 2 quarters · filed 2023-11-17 | $361.10K 10-Q · filed 2023-11-17 | $562.93K derived: sum of 4 quarters · filed 2023-11-17 | |
| 2022-06-30 | $139.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-10-20 | $491.76K 10-Q · filed 2023-10-20 | $693.59K derived: sum of 3 quarters · filed 2023-10-20 | $841.51K derived: sum of 4 quarters · filed 2023-10-20 | |
| 2022-03-31 | $351.82K 10-Q · filed 2023-05-12 | $553.64K derived: sum of 2 quarters · filed 2023-05-12 | $701.57K derived: sum of 3 quarters · filed 2023-05-12 | $646.12K derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | $201.83K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $349.75K derived: sum of 2 quarters · filed 2023-03-09 | $294.30K derived: sum of 3 quarters · filed 2023-03-09 | $336.71K 10-K · filed 2023-03-09 | |
| 2021-09-30 | $147.93K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $92.48K derived: sum of 2 quarters · filed 2022-11-14 | $134.89K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$55.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$13.04K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $42.41K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |